Brief: Spago Nanomedical Q1 Sales SEK 22 Thousand
07/05/2026 07:00
May 07 (Reuters) - Spago Nanomedical Q1 operating expenses SEK -7.967 million. Q1 adjusted EPS SEK -0.01 Q1 net income SEK -6.798 million
Recent news on Spago Nanomedical AB (publ)
See all newsBrief: Spago Nanomedical Announces Outcome Of Rights Issue
Brief: Spago Nanomedical Resolves On Rights Issue Of About SEK 16 Million
Sweden's Spago Nanomedical Q1 loss narrows
Brief: Spago Nanomedical Q1 Sales SEK 22 Thousand
Brief: Spago Nanomedical Says Tumorad-01 Study Meets Primary Endpoint Of Maximum Tolerated Dose